SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Role of autologous platelet-rich plasma for recurrent or refractory macular hole in the era of various flap techniques: a meta-analysis.
Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effects of autologous platelet-rich plasma (PRP) application on recurrent or refractory full-thickness macular hole (FTMH) in patients who had undergone vitrectomy and internal limiting membrane (ILM) peeling.
methodsDatabases including PubMed, EMBASE, and Cochrane Library were searched on April 10, 2025. Studies that investigated the effects of autologous PRP or whole blood application to treat recurrent or refractory FTMH were included. The primary outcome was the closure rate with the procedure, and a meta-analysis of proportions was performed to estimate pooled closure rates.
resultsAmong preliminary identification of 222 studies, 10 case series using autologous PRP only and three studies using autologous PRP/whole blood and additional flap or graft (retina, lens capsule, amniotic membrane, or residual ILM) were included in the meta-analysis. The overall pooled closure rate with autologous PRP application was 85% (95 confidence interval [CI]: 75-93%), while the additional use of a flap or graft led to an 87% closure rate (95% CI: 64-100%) in cases presenting with recurrent or refractory FTMH. There were no significant differences in closure rate of recurrent or refractory FTMH between groups (p = 0.820). No adverse effects were reported regarding the use of autologous PRP or whole blood application.
conclusionThe use of autologous PRP with or without additional flaps was as effective to achieve anatomical closure of recurrent or refractory FTMH, without the need for the concurrent flap or graft techniques.
Indexed as
Identifiers
41999418What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.